Tarceva (erlotinib) is a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Tarceva is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC).
Tarceva EU indications
- Tarceva is approved for the first-line treatment of EGFR mutation-positive NSCLC1
- Tarceva is also indicated for the treatment of NSCLC in the post-platinum setting (maintenance, second-line and third-line), regardless of mutation status1
- Tarceva is indicated, in combination with gemcitabine, for the treatment of patients with metastatic pancreatic cancer1
- Tarceva® (erlotinib) Summary of Product Characteristics, F. Hoffmann-La Roche Ltd., 2011.